23 completed, 2 recruiting, 2 terminated, 2 unknown. 29 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 29 | Completed 23, Recruiting 2, Terminated 2, Unknown 2 |
| Phase 3 | 2 | Completed 2 |
Follow Ezetimibe: new trials by email Literature Review of Ezetimibe trials Research Report on Ezetimibe
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Early Statin-Ezetimibe Combination vs. Statin Monotherapy in Stroke With Atherosclerosis statin + ezetimibe, Statin monotherapy (rosuvastatin or atorvastatin) - Ischemic Stroke, Hypercholesteremia | Phase 2 | Recruiting | Chang Gung Memorial Hospital | 300 | 2025-08-01 | 2025-12-30 |
| Intensive Cholesterol-Lowering and CD8+ T Cells in Prostate Cancer Vytorin, Ezetimibe - Prostate Cancer | Phase 2 | Recruiting | Cedars-Sinai Medical Center | 140 | 2024-07-16 | 2026-03-11 |
| Study of HSK31679 in Subjects With Hypercholesterolemia With Nonalcoholic Fatty Liver Disease（NAFLD） HSK31679 low dose, HSK31679 medium dose, HSK31679 high dose - Hypercholesterolemia | Phase 2 | Completed | Haisco Pharmaceutical Group Co., Ltd. | 210 | 2023-04-26 | 2024-04-09 |
| Study to Evaluate the Effect of Obicetrapib in Combination With Ezetimibe as an Adjunct to HIS Therapy Obicetrapib, Ezetimibe 10mg, Obicetrapib placebo - Dyslipidemias, High Cholesterol | Phase 2 | Completed | NewAmsterdam Pharma | 119 | 2022-03-09 | 2024-07-03 |
| Randomized Study of Obicetrapib in Combination With Ezetimibe Obicetrapib 5mg, Ezetimibe 10mg, Placebo - Dyslipidemias, High Cholesterol | Phase 2 | Completed | NewAmsterdam Pharma | 112 | 2021-02-23 | 2024-04-24 |
| A Study to Evaluate the Safety and Efficacy of the PCSK9 Inhibitor AK102 in Patients With HoFH AK102, Statins, Ezetimibe - Homozygous Familial Hypercholesterolemia | Phase 2 | Completed | Akeso | 10 | 2019-05-13 | 2023-03-02 |
| Bempedoic Acid + Ezetimibe Fixed-Dose Combination (FDC) Study in Patients With Type 2 Diabetes and Elevated LDL-C Bempedoic acid + Ezetimibe FDC Oral Tablet, Ezetimibe 10 mg Oral Tablet, Placebo Oral Tablet - Diabetes, Diabetes Mellitus, Type 2 | Phase 2 | Completed | Esperion Therapeutics, Inc. | 242 | 2018-05-09 | 2020-04-09 |
| Ezetimibe as a Safe and Efficacious Treatment for Chronic Hepatitis C 20mg ezetimibe, Placebo, 40mg ezetimibe - Chronic Hepatitis C | Phase 2 | Terminated | VA Office of Research and Development | 2 | 2018-04-16 | 2022-06-06 |
| Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180mg, Ezetimibe 10mg, and Atorvastatin 20 mg Triplet Therapy in Patients With Elevated LDL-C Bempedoic acid 180mg, Ezetimibe 10mg, Atorvastatin 20mg - Hypercholesterolemia | Phase 2 | Completed | Esperion Therapeutics, Inc. | 63 | 2017-01-19 | 2020-04-03 |
| Ezetimibe for Patients With Chronic Hepatitis D Ezetimibe - Chronic Hepatitis D | Phase 2 | Unknown | Ziauddin Hospital | 20 | 2017-01-01 | 2017-04-04 |
| An 8-Week Dose-Finding Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia alirocumab SAR236553 (REGN727), statins, ezetimibe - Hypercholesterolaemia | Phase 2 | Completed | Sanofi | 42 | 2016-09-15 | 2019-09-06 |
| Pegylated Interferon Alone or in Combination With Ezetimibe for Patients With Chronic Hepatitis D Pegylated interferon alfa, Ezetimibe - Hepatitis D, Chronic | Phase 2 | Unknown | Aga Khan University | 20 | 2016-01-01 | 2017-04-07 |
| Ezetimibe-Ursodiol Combination Therapy on Biomarkers of Liver Function and Sterol Balance in Subjects With NAFLD EZ-Urso combination therapy - Nonalcoholic Fatty Liver Disease (NAFLD) | Phase 2 | Terminated | Gregory Graf, PhD | 2 | 2014-09-01 | 2018-02-07 |
| Dose Ranging Study Of Bococizumab (PF-04950615; RN316) In Hypercholesterolemic Japanese Subjects Bococizumab (PF-04950615;RN316), Placebo, Ezetimibe - Hypercholesterolemia | Phase 2 | Completed | Pfizer | 218 | 2014-03-01 | 2019-02-08 |
| Evaluation of ETC-1002, Ezetimibe, and the Combination in Hypercholesterolemic Patients ETC-1002, Ezetimibe - Hypercholesterolemia | Phase 2 | Completed | Esperion Therapeutics, Inc. | 349 | 2013-09-01 | 2019-03-29 |
| A Study of LY3015014 in Participants With High Cholesterol LY3015014, Placebo, Statin - Hypercholesterolemia | Phase 2 | Completed | Eli Lilly and Company | 527 | 2013-06-01 | 2019-09-18 |
| Ezetimibe Versus Placebo in the Treatment of Non-alcoholic Steatohepatitis Ezetimibe - Non Alcoholic Steatohepatitis | Phase 2 | Completed | University of California, San Diego | 50 | 2013-01-01 | 2020-07-14 |
| Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects Evolocumab, Ezetimibe, Placebo to Evolocumab - Hyperlipidemia | Phase 2 | Completed | Amgen | 160 | 2011-07-28 | 2022-11-07 |
| Monoclonal Antibody Against PCSK9 to Reduce Elevated Low-density Lipoprotein Cholesterol (LDL-C) in Adults Currently Not Receiving Drug Therapy for Easing Lipid Levels Evolocumab, Ezetimibe, Placebo to Evolocumab - Hyperlipidemia | Phase 2 | Completed | Amgen | 411 | 2011-07-06 | 2022-11-08 |
| A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Administering Multiple Oral Doses of GSK1292263 Alone and With Atorvastatin 10mg atorvastatin, 80mg atorvastatin, GSK1292263 Placebo - Dyslipidaemias, Dyslipidemias | Phase 2 | Completed | GlaxoSmithKline | 287 | 2010-09-14 | 2019-07-16 |
Showing 20 of 29. Sign in to see all of them.
Hypercholesterolemia (14) · Dyslipidemias (4) · Hyperlipidemias (4) · Atherosclerosis (3) · Non-alcoholic Fatty Liver Disease (3) · Diabetes Mellitus, Type 2 (2) · Hepatitis D (2) · Hepatitis D, Chronic (2) · Hypercholesterolemia, Autosomal Dominant, 3 (2) · Coronary Artery Disease (1) · Diabetes Mellitus (1) · Hepatitis C (1) · Hepatitis C, Chronic (1) · Homozygous Familial Hypercholesterolemia (1) · Hypertriglyceridemia (1)
Aegerion Pharmaceuticals, Inc. (3) · Esperion Therapeutics, Inc. (3) · Amgen (2) · NewAmsterdam Pharma (2) · Sanofi (2) · Aga Khan University (1) · Akeso (1) · Cedars-Sinai Medical Center (1) · Chang Gung Memorial Hospital (1) · Eli Lilly and Company (1) · GlaxoSmithKline (1) · Gregory Graf, PhD (1) · Haisco Pharmaceutical Group Co., Ltd. (1) · Jose Rocha Faria Neto (1) · Karo Bio AB (1)
United States (18) · Canada (4) · Denmark (3) · Netherlands (3) · Sweden (3) · Australia (2) · Belgium (2) · China (2) · Czechia (2) · Japan (2) · Russia (2) · Spain (2) · Brazil (1) · Chile (1) · Finland (1)
Ron Haberman, MD (2) · Barry Lubin, MD (1) · Diane E MacDougall, MS (1) · Eli Roth, MD (1) · Frederick F Samaha, M.D. (1) · Gregory Graf, PhD (1) · Hyung Kim, MD (1) · Jackson Downey, MD (1) · James McKenney, Pharm D (1) · Jens D Kristensen, MD, PhD (1)
PMID 20435205, PMID 20566677, PMID 26929777, PMID 27206943, PMID 28539539, PMID 31549625, PMID 32331936, PMID 35188949, PMID 36318027, PMID 37994400, PMID 40846146, PMID 41190670
2015 (1), R01CA280060 (1)